AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19065903 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg per day
Number of subjects: 145
Study 19065903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study 16317530 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dorsal instrumentation (PER-G)
Number of subjects: 57
Study 16317530 — intervention group
Group type: COMPARATOR
Intervention: Open procedure (OP-G)
Number of subjects: 57
Study 12798078 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 40
Study 10892945 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 parts per million inhaled nitric oxide
Number of subjects: 40
Study 10892945 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 40
Study 9181997 — intervention group
Group type: EXPERIMENTAL
Intervention: BV pacing
Number of subjects: 8
Study 9181997 — intervention group
Group type: COMPARATOR
Intervention: Standard RV pacing
Number of subjects: 8
Study 9181997 — intervention group
Group type: COMPARATOR
Intervention: BV pacing off
Number of subjects: 8
Study 9181997 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 +/- 6 months
Number of subjects: 8
Study 1329478 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 5‐20 mg once daily
Number of subjects: 278
Study 1329478 — intervention group
Group type: COMPARATOR
Intervention: enalapril 5‐20 mg once daily
Number of subjects: 278
Study 3864225 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sodium restriction from 200 to 50 mmol/day over 2 weeks in subjects with heredity of hypertension
Number of subjects: 62
Study 3864225 — intervention group
Group type: COMPARATOR
Intervention: Moderate sodium restriction from 200 to 50 mmol/day over 2 weeks in subjects without heredity of hypertension
Number of subjects: 62
Study 3864225 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to usual high sodium diet after 2 weeks of sodium restriction
Number of subjects: 62
Study 31399377 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine
Number of subjects: 569
Study 31399377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study 29860922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant
Number of subjects: 726
Study 29860922 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 726
Study 27887620 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training
Number of subjects: 0
Study 27887620 — intervention group
Group type: COMPARATOR
Intervention: Lecture only
Number of subjects: 0
Study 27887620 — intervention group
Group type: COMPARATOR
Intervention: Lecture + e-module
Number of subjects: 0
Study 27887620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture + skills training + e-module
Number of subjects: 0
Study 24804884 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate online MBCR (n = 30)
Number of subjects: 62
Study 24804884 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n = 32)
Number of subjects: 62
Study 22492366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkles micronutrient powder (MNP)
Number of subjects: 1063
Study 22492366 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1063
Study 19660268 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional thoracic sympathectomy
Number of subjects: 32
Study 19660268 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified thoracic sympathectomy
Number of subjects: 32
Study 18822978 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (Madopa)
Number of subjects: 60
Study 18822978 — intervention group
Group type: COMPARATOR
Intervention: Medication (Madopa)
Number of subjects: 60
Study 16103254 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection
Number of subjects: 191
Study 12494258 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 0
Study 10450448 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ivermectin (up to 1600 micrograms/kg bodyweight)
Number of subjects: 100
Study 10450448 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of ivermectin (150 micrograms/kg bodyweight)
Number of subjects: 100
Study 7590390 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ultrafiltrates collected 20 min after reperfusion
Number of subjects: 0
Study 7590390 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-containing postreperfusion samples from patients
Number of subjects: 0
Study 7590390 — intervention group
Group type: COMPARATOR
Intervention: Superoxide dismutase
Number of subjects: 0
Study 3130257 — intervention group
Group type: EXPERIMENTAL
Intervention: BAYo1248 (40 mg before breakfast)
Number of subjects: 17
Study 3130257 — intervention group
Group type: EXPERIMENTAL
Intervention: BAYm1099 (100 mg before breakfast and dinner)
Number of subjects: 17
Study 3130257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind crossover study)
Number of subjects: 17
Study 28450388 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-tolerant assay for detecting anti-drug antibodies (ADAs)
Number of subjects: 76
Study 28450388 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-tolerant assay after optimization
Number of subjects: 76
Study 28450388 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-tolerant assay at the end of TAXIT
Number of subjects: 76
Study 28450388 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA Q4 patients
Number of subjects: 76
Study 28450388 — intervention group
Group type: COMPARATOR
Intervention: ADA-negative patients and ADA Q1/Q2 patients
Number of subjects: 76
Study 27061185 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized, patient-centered intervention educating Veterans about metabolic side effects and encouraging advocacy for monitoring
Number of subjects: 0
Study 27061185 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control group)
Number of subjects: 0
Study 25656074 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person visits at home and/or in the community plus telephone and mail
Number of subjects: 151
Study 25656074 — intervention group
Group type: COMPARATOR
Intervention: Telephone and mail only
Number of subjects: 151
Study 23743803 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-20 mmol sodium diet and sodium tablets (180 mEq/day)
Number of subjects: 32
Study 23743803 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo tablets
Number of subjects: 32
Study 19475576 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in incontinence episode frequency (IEF) >40% to <=50%
Number of subjects: 1913
Study 19475576 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in IEF >70%
Number of subjects: 1913
Study 19475576 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in IEF >70% to <=80%
Number of subjects: 1913
Study 19475576 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in IEF >90% to <=100%
Number of subjects: 1913
Study 19475576 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in IEF <=40%
Number of subjects: 1913
Study 17936036 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Umbilical Vein (HUV) prosthesis
Number of subjects: 129
Study 17936036 — intervention group
Group type: COMPARATOR
Intervention: Heparin-Bonded Dacron (HBD) prosthesis
Number of subjects: 129
Study 17936036 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 129
Study 20426759 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment interruption for > or =96 weeks
Number of subjects: 38
Study 20426759 — intervention group
Group type: COMPARATOR
Intervention: Maintained antiretroviral therapy
Number of subjects: 38
Study 15597104 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg m(‐2))
Number of subjects: 108
Study 15597104 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, irinotecan, and lenogastrim (60 mg m(‐2), 200 mg m(‐2), and 150 microg m(‐2) day(‐1), respectively)
Number of subjects: 108
Study 12110110 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate, 1000 mg intravenously
Number of subjects: 120
Study 12110110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% physiological saline, 10 ml)
Number of subjects: 120
Study 9692160 — intervention group
Group type: COMPARATOR
Intervention: Fansidar alone
Number of subjects: 405
Study 9692160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar plus chloroquine
Number of subjects: 405
Study 7928871 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 10
Study 7928871 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg propranolol
Number of subjects: 10
Study 7928871 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 10
Study 7928871 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg propranolol
Number of subjects: 10
Study 7928871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3349842 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped programs on bronchoscopic anatomy and pathology
Number of subjects: 65
Study 3349842 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 65
Study 11773918 — intervention group
Group type: EXPERIMENTAL
Intervention: Efegatran sulfate (overall)
Number of subjects: 336
Study 11773918 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 336
Study 11773918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose efegatran
Number of subjects: 336
Study 11773918 — intervention group
Group type: EXPERIMENTAL
Intervention: Efegatran sulfate (high-dose)
Number of subjects: 336
Study 11773918 — intervention group
Group type: EXPERIMENTAL
Intervention: Efegatran sulfate
Number of subjects: 336
Study 29975272 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB alone (15 mL of 0.5% bupivacaine)
Number of subjects: 155
Study 29975272 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB+PAI (15 mL of 0.5% bupivacaine + 50 mL of 0.25% bupivacaine with epinephrine)
Number of subjects: 155
Study 29975272 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI alone (50 mL of 0.25% bupivacaine with epinephrine)
Number of subjects: 155
Study 29975272 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB+PAI
Number of subjects: 155
Study 29975272 — intervention group
Group type: COMPARATOR
Intervention: ACB alone
Number of subjects: 155
Study 29975272 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI alone
Number of subjects: 155
Study 26559637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily after breakfast
Number of subjects: 409
Study 26559637 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily after breakfast
Number of subjects: 409
Study 26559637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 or 20 mg as maintenance therapy
Number of subjects: 409
Study 24496699 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg once daily for 4 weeks, followed by titration to 400 mg for the next 8 weeks.
Number of subjects: 432
Study 24496699 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 20 mg once daily for 4 weeks, followed by titration to 40 mg for the next 8 weeks.
Number of subjects: 432
Study 24496699 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg once daily, titrated to 400 mg, and olmesartan 20 mg, titrated to 40 mg, with possible addition of amlodipine (2.5-5 mg) and hydrochlorothiazide (6.25-25 mg) if BP target not attained.
Number of subjects: 432
Study 23278573 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 0
Study 23278573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20615859 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 33
Study 20615859 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 33
Study 19103535 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin every other day
Number of subjects: 61
Study 19103535 — intervention group
Group type: COMPARATOR
Intervention: 20 mg atorvastatin daily
Number of subjects: 61
Study 19103535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 61
Study 15829861 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs)
Number of subjects: 469
Study 15829861 — intervention group
Group type: COMPARATOR
Intervention: Single-vision lenses (SVLs)
Number of subjects: 469
Study 12028506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 537
Study 10452673 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg twice a day (H2RA)
Number of subjects: 71
Study 10452673 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily (PPI)
Number of subjects: 71
Study 10452673 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori (+) patients with Famotidine
Number of subjects: 71
Study 10452673 — intervention group
Group type: COMPARATOR
Intervention: H. pylori (+) patients with Omeprazole
Number of subjects: 71
Study 10452673 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily drinkers
Number of subjects: 71
Study 10452673 — intervention group
Group type: EXPERIMENTAL
Intervention: Social drinkers
Number of subjects: 71
Study 8520639 — intervention group
Group type: EXPERIMENTAL
Intervention: Air filled balloon (n = 11)
Number of subjects: 20
Study 8520639 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (n = 9)
Number of subjects: 20
Study 8520639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 2201825 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 0
Study 2201825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive timed sequential treatment using high dose cytarabine
Number of subjects: 0
Study 2201825 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials
Number of subjects: 0
Study 334638 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 23
Study 334638 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 23
Study 334638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31145382 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted band squat
Number of subjects: 11
Study 31145382 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted countermovement jumps
Number of subjects: 11
Study 31145382 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop jumps from a 45-cm box
Number of subjects: 11
Study 31145382 — intervention group
Group type: COMPARATOR
Intervention: Swim-specific control
Number of subjects: 11
Study 31774468 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat hepatectomy
Number of subjects: 240
Study 31774468 — intervention group
Group type: COMPARATOR
Intervention: PRFA
Number of subjects: 240
Study 31324358 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dipyridamole stress echocardiography (0.84 mg/kg)
Number of subjects: 3059
Study 25855466 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive maxillary plates (IO+) during the first year of life
Number of subjects: 54
Study 25855466 — intervention group
Group type: COMPARATOR
Intervention: No passive maxillary plates (IO-) during the first year of life
Number of subjects: 54
Study 23486302 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (WBV) with exercise training for 15 minutes, 3 days per week for 8 weeks
Number of subjects: 82
Study 23486302 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercise without WBV)
Number of subjects: 82
Study 23486302 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (WBV) with exercise training
Number of subjects: 82
Study 21658558 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile <7 (n = 854)
Number of subjects: 2627
Study 21658558 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile ≥ 7 and <13 (n = 825)
Number of subjects: 2627
Study 21658558 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score tertile ≥ 13 (n = 948)
Number of subjects: 2627
Study 19454777 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on the dominant leg (UNID)
Number of subjects: 10
Study 19454777 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on the nondominant leg (UNIND)
Number of subjects: 10
Study 19454777 — intervention group
Group type: COMPARATOR
Intervention: Bipedal stance
Number of subjects: 10
Study 16676791 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 76
Study 16676791 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen at 3 L per minute
Number of subjects: 76
Study 16676791 — intervention group
Group type: COMPARATOR
Intervention: Placebo-CPAP
Number of subjects: 76
Study 14579160 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal corticosteroid injection
Number of subjects: 31
Study 14579160 — intervention group
Group type: COMPARATOR
Intervention: Interspinous corticosteroid injection
Number of subjects: 31
Study 10627112 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancy variables
Number of subjects: 100
Study 10627112 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-participant drinking
Number of subjects: 100
Study 10627112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual arousal
Number of subjects: 100
Study 9132089 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical contrast-enhanced CT
Number of subjects: 53
Study 9132089 — intervention group
Group type: COMPARATOR
Intervention: Gradient-echo MR
Number of subjects: 53
Study 9132089 — intervention group
Group type: COMPARATOR
Intervention: Vascular MR experts
Number of subjects: 53
Study 9132089 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced CT experts
Number of subjects: 53
Study 1381218 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant consensus interferon (rIFN-con-1)
Number of subjects: 10
Study 1381218 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon-alpha-2b (r-IFN-alpha-2b)
Number of subjects: 10
Study 1381218 — intervention group
Group type: EXPERIMENTAL
Intervention: granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 10
Study 6208742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anesthesia with HDHE
Number of subjects: 120
Study 6208742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anesthesia with dextran 70
Number of subjects: 120
Study 6208742 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive anesthesia with HDHE
Number of subjects: 120
Study 6208742 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive anesthesia with dextran 70
Number of subjects: 120
Study 6208742 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with HDHE
Number of subjects: 120
Study 6208742 — intervention group
Group type: COMPARATOR
Intervention: Thromboprophylaxis with dextran 70
Number of subjects: 120
Study 6208742 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 31239114 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physical exercise program (1-hour sessions, moderate intensity, twice a week for 12 weeks)
Number of subjects: 56
Study 31239114 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; no intervention)
Number of subjects: 56
Study 29090526 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with radiation therapy (RT)
Number of subjects: 44
Study 29090526 — intervention group
Group type: COMPARATOR
Intervention: Historical control (not specified treatment)
Number of subjects: 44
Study 29090526 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with RT
Number of subjects: 44
Study 27636922 — intervention group
Group type: EXPERIMENTAL
Intervention: Decimeter wave therapy and halotherapy in addition to basic drug treatment
Number of subjects: 36
Study 27636922 — intervention group
Group type: COMPARATOR
Intervention: Basic drug therapy
Number of subjects: 36
Study 25340337 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting intervention by community health workers (CHWs) trained in cognitive-behavioral strategies, in addition to clinic care.
Number of subjects: 1238
Study 25340337 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting intervention among women living with HIV.
Number of subjects: 1238
Study 25340337 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of home visits received.
Number of subjects: 1238
Study 25340337 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving healthcare at clinics.
Number of subjects: 1238
Study 23145504 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing classes
Number of subjects: 24
Study 23145504 — intervention group
Group type: COMPARATOR
Intervention: Film club
Number of subjects: 24
Study 20701902 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled tubular compression stocking
Number of subjects: 55
Study 20701902 — intervention group
Group type: COMPARATOR
Intervention: Conventional compression bandage for one week
Number of subjects: 55
Study 20701902 — intervention group
Group type: COMPARATOR
Intervention: Conventional compression bandage replaced by controlled tubular compression stocking at 5h
Number of subjects: 55
Study 17950857 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg pitrakinra (subcutaneous injection once daily)
Number of subjects: 56
Study 17950857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection once daily)
Number of subjects: 56
Study 17950857 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg pitrakinra (nebulisation twice daily)
Number of subjects: 56
Study 17950857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nebulisation twice daily)
Number of subjects: 56
Study 17950857 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of pitrakinra
Number of subjects: 56
Study 17950857 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of pitrakinra
Number of subjects: 56